Replies to post #299036 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Ex, Tumor shrinkage??? Maybe you missed the fact that the tumor is removed before DCVaxL is given??. Yes, they have to use a different metric than RECIST for tumor shrinkage. What about time to tumor return? Or length of survival? They have two Phase 1s in L and the Ph. I ovarian trial that showed 85% of patients lived longer on DCVaxL. And we know some from the brain cancer trial are still alive. The doctors and management also have compassionate care patients. They also have the unblinded data from the spring refreshes that showed patients living longer with no obvious reason why from known factors. Trials have been using time to recurrence and survival time to measure the success of treatment for decades. RECIST doesn’t even apply here. But that hasn’t stopped you from using this argument before.